Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics has appointed radiopharmaceutical expert Dr. Svetlana Selivanova to its board, enhancing its strategic focus on developing targeted therapies. This move is expected to strengthen the company’s radiopharmaceutical programs and accelerate progress using their proprietary Accum technology.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
